|
Oct 10
|
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
|
|
Oct 3
|
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
|
|
Jul 26
|
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
|
|
Jul 24
|
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
|
|
Jun 27
|
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
|
|
Jun 25
|
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
|
|
May 7
|
All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy
|
|
May 7
|
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
|
|
May 6
|
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
|
|
Mar 8
|
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
|
|
Dec 12
|
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
|
|
Dec 7
|
ALLR: Stenoparib Clinical Update
|
|
Dec 5
|
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
|